Revolution Medicines Formally Issues $500M Convertible Notes at Premium Above 52-Week High
RVMD has more than doubled off its 52-week low of $34.
Summary
Revolution Medicines formally issued $500 million in 0.50% Convertible Senior Notes due 2033, part of a larger capital raise, with a conversion price set at a significant premium above its 52-week high, signaling strong investor confidence.
Key Events · Financing and Capital Events · RVMD
-
Issuance of Convertible Senior Notes
Revolution Medicines, Inc. formally issued $500,000,000 aggregate principal amount of its 0.50% Convertible Senior Notes due 2033.
-
Conversion Terms
The notes have an initial conversion rate of 5.0302 shares of common stock per $1,000 principal amount, equating to an initial conversion price of approximately $198.80 per share.
-
Premium Conversion Price
The conversion price of $198.80 per share is set at a significant premium to the current stock price of $151.17 and above the company's 52-week high of $155.70, indicating strong investor confidence.
-
Part of Larger Capital Raise
This issuance is a component of the company's recently announced upsized public offerings, which are expected to secure approximately $2.2 billion in total capital, following positive clinical trial results.
Analysis · RVMD · Life Sciences
This 8-K formally documents the issuance of $500 million in 0.50% Convertible Senior Notes due 2033, a key part of Revolution Medicines' recently announced $2.2 billion capital raise. The notes feature an initial conversion price of approximately $198.80 per share, which is a substantial premium not only to the current stock price of $151.17 but also above the company's 52-week high of $155.70. This premium conversion price reflects strong institutional confidence in the company's long-term growth prospects, especially following highly positive clinical trial results. The financing provides significant capital to support the company's research and development, potential commercialization efforts, and general corporate purposes, extending its operational runway.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RVMD was trading at $151.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $29.5B. The 52-week trading range was $34.00 to $155.70. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.